Bavarian Nordic to start phase III with Covid-19 booster in June
Bavarian Nordic is aiming to demonstrate that its Covid-19 booster vaccine candidate ABNCov2 is just as good as Pfizer’s.
by christian bundgaard, translated by daniel pedersen
Danish biotech firm Bavarian Nordic will begin a phase III trial of its Covid-19 vaccine in June, 2022, according to database Clinical Trials.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
